1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Nanjing Vishee Medical Technology Co., Ltd. Class A

Nanjing Vishee Medical Technology Co., Ltd. Class A

SSSE:688580
40.29
CNY
-0.07
(-0.17%)
1.80EPS
29.61P/E
5.10BMarket Cap
Oct 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.7
0.84
1.14
1.37
2.03
2.9
4.44
4.63
4.49
3.36
4.84
4.2
4.83
5
Basic EPS, GAAP
0.2
0.31
0.4
0.33
0.57
0.88
1.39
1.76
1.86
0.98
1.43
1.07
1.44
1.8
Free Cash Flow per Basic Share
0.08
0.06
0.21
0.19
0.53
0.63
1.68
1.33
0.73
-0.1
0.01
0.05
0.61
- -
Dividend per Share
0.04
0.06
0.31
0.12
0.35
0.29
0.48
0.62
0.75
0.93
0.53
1.07
0.8
-0.01
Book Value per Share
0.54
0.87
1.52
1.69
2.01
2.61
3.47
14.69
16.02
15.91
16.93
16.99
17.68
17.66
Tangible Book Value per Share
0.53
0.7
1.35
1.53
1.71
2.34
3.21
14.49
15.83
14.08
14.96
14.94
15.59
15.65
Basic Weighted Avg Shares
70
69
70
70
71
72
72
82
96
96
96
95
96
96
Sales/Revenue/Turnover
49
58
81
96
144
208
319
378
430
322
462
400
463
478
Operating Margin (%)
13.96
22.37
29.62
19.05
31.44
33.29
34.87
38.64
36.84
21.83
26.62
22.65
28.82
29.62
Depreciation Expense
1
1
1
1
1
4
8
9
11
17
20
22
28
- -
Net Income, GAAP
14
22
28
23
40
63
100
144
178
94
136
102
138
172
Effective Tax Rate (%)
4.29
3.4
7.34
14.05
14.01
14.5
13.86
13.82
10.05
11.35
9.17
9.98
10.59
11.88
Profit Margin (%)
28.64
37.4
34.94
24.14
27.92
30.5
31.27
37.97
41.35
29.17
29.48
25.49
29.84
36
Working Capital
34
47
79
56
82
91
139
1,289
1,330
1,190
1,103
972
900
860
LT Debt
- -
- -
- -
- -
20
14
4
3
2
- -
- -
1
- -
- -
Total Equity
39
62
106
118
153
196
255
1,411
1,533
1,529
1,627
1,627
1,693
1,691
Return on Invested Capital (%)
- -
31.58
28.24
14.79
26.36
30.59
39.02
16.51
11.67
5.95
8.45
6.08
8.09
10.02
Return on Capital (%)
- -
43.25
33.55
20.54
27.66
33.17
41.82
17.17
12.08
6.14
8.71
6.28
8.31
10.21
Return on Common Equity (%)
- -
43.93
33.65
20.63
30.76
38.23
45.67
17.36
12.1
6.13
8.64
6.27
8.32
10.27

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
96
96
96
Market Capitalization
4,635
4,887
5,102

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,115
1,032
962
Cash, Cash Equivalents & STI
1,023
931
860
Accounts Receivable, Net
17
21
24
Inventories
42
37
41
Total Current Liabilities
215
107
103
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
57.13%
3.77%
4.03%
Free Cash Flow
174.19%
279.09%
1,024.89%
Net Income, GAAP
24.71%
6.4%
35.41%
Sales/Revenue/Turnover
22.01%
6.88%
15.66%
Total Cash Common Dividend
32.54%
19.83%
-25.08%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
88
104
100
108
400
2025
96
115
- -
137
463
2026
106
120
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
0.29
0.3
0.25
1.07
2025
0.35
0.38
- -
0.38
1.44
2026
0.64
0.4
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.07
2025
- -
- -
- -
-0.01
0.8
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Zhi Yu Wang
Full Time Employees
635
Sector
Health technology
Industry
Medical specialties
Address
Building 9 Nanjing JS China 210012
IPO Date
Jul 21, 2020
Website
vishee.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Nanjing Vishee Medical Technology Co., Ltd engages primarily in the development, manufacture, and sale of medical devices and diagnostic solutions. Its core products include in vitro diagnostic reagents; medical testing kits covering a broad spectrum of clinical and biochemical markers; rapid detection test kits; automated analyzers; and related consumables. The company serves healthcare providers across hospitals, clinical laboratories, and healthcare institutions primarily in China, with expanding efforts in international markets. Founded in 2008 and headquartered in Nanjing, Jiangsu Province, Nanjing Vishee Medical Technology focuses on offering integrated diagnostic products and services that improve disease detection efficiency and accuracy. In the last two years, Nanjing Vishee Medical Technology has bolstered its market presence through strategic partnerships aimed at expanding its diagnostic portfolio and geographic reach. The company has launched new rapid detection products aligned with emerging infectious diseases and chronic condition diagnostics, reflecting a significant product innovation push. Operationally, it has strengthened its R&D capabilities and expanded manufacturing capacity to support growing demand. These efforts have positioned it competitively within the Chinese medical technology industry while setting foundations for international expansion and diversification of its diagnostic technology offerings. Nanjing Vishee Medical Technology operates within the medical devices and healthcare diagnostic industry segment, targeting hospitals, diagnostic labs, and health service providers. It maintains a comprehensive product portfolio catering to various clinical needs, including immunoassay, biochemical tests, molecular diagnostics, and point-of-care testing solutions. The company leverages advanced technology platforms to deliver precision diagnostics, contributing to improved clinical decision-making and patient outcomes. Its subsidiary and business partnerships further support product development and market distribution in China and select global regions. Overall, Nanjing Vishee Medical Technology Co., Ltd combines a robust suite of diagnostic reagents and testing systems with a strategic focus on innovation and market expansion since its founding in 2008, making it a significant player in China's medical diagnostic technology sector headquartered in Nanjing, Jiangsu. Recent enhancements in product launches and strategic alliances underscore its commitment to growth and increased market relevance.